Diabetes Care, Vol 19, Issue 8 849-856, Copyright © 1996 by American Diabetes Association

ARTICLES

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group

RB Goldberg, SM Holvey and J Schneider
Diabetes Research Institute, University of Miami School of Medicine, Florida 33136, USA.

OBJECTIVE: To assess the efficacy, safety, and dose-response relationship of glimepiride in patients with NIDDM. RESEARCH DESIGN AND METHODS: After a 21-day placebo washout period, 304 patients were randomized to receive either placebo or glimepiride, 1, 4, or 8 mg once daily. Fasting plasma glucose (FPG), 2-h postprandial glucose (PPG), and HbA1c were measured at predetermined intervals during the washout period and the 14-week study. Adverse events were tabulated. RESULTS: At each patient visit, reduction from baseline FPG was greater in each glimepiride group than in the placebo group (P < 0.001). Changes from baseline to endpoint after 1, 4, and 8 mg glimepiride exceeded those after placebo (P < 0.001) by 2.4, 3.9, and 4.1 mmol/l, respectively, for FPG; by 1.2, 1.8, and 1.9 percentage points, respectively, for HbA1c; and by 3.5, 5.1, and 5.2 mmol/l, respectively, for 2-h PPG. Greater reductions in these parameters were observed with 8 and 4 mg than with 1 mg (P < 0.05), indicating a dose-response relationship. When patients with baseline HbA1c levels > or = 8% were assessed, more patients who received 8 mg glimepiride had HbA1c values < 8% at endpoint compared with patients receiving 4 mg. Glimepiride had a favorable safety profile. CONCLUSIONS: Glimepiride in 1-, 4-, or 8-mg doses was effective and well tolerated. Although the 4- and 8-mg once-daily doses were significantly more potent than the 1-mg dose, all three doses yielded clinical improvement. Because the 8-mg dose controlled HbA1c values in a greater number of patients with high baseline HbA1c levels than did the 4-mg dose, this higher dose might be beneficial for patients who are difficult to treat.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. F. Kruger Exploring the Pharmacotherapeutic Options for Treating Type 2 Diabetes The Diabetes Educator, May 1, 2008; 34(Supplement_3): 60S - 65S. [Abstract] [Full Text] [PDF]

				M. C. Riddle Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?: An argument in favor Diabetes Care, February 1, 2008; 31(Supplement_2): S125 - S130. [Full Text] [PDF]

				W. L. Baker, G. Gutierrez-Williams, C. M. White, J. Kluger, and C. I. Coleman Effect of Cinnamon on Glucose Control and Lipid Parameters Diabetes Care, January 1, 2008; 31(1): 41 - 43. [Abstract] [Full Text] [PDF]

				S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D. R. Matthews Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care, June 1, 2004; 27(6): 1335 - 1342. [Abstract] [Full Text] [PDF]

				M. T. Sheehan Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach Clin. Med. Res., July 1, 2003; 1(3): 189 - 200. [Abstract] [Full Text] [PDF]

				A. Haupt, C. Kausch, D. Dahl, O. Bachmann, M. Stumvoll, H.-U. Haring, and S. Matthaei Effect of Glimepiride on Insulin-Stimulated Glycogen Synthesis in Cultured Human Skeletal Muscle Cells: A comparison to glibenclamide Diabetes Care, December 1, 2002; 25(12): 2129 - 2132. [Abstract] [Full Text] [PDF]

				M. Korytkowski, A. Thomas, L. Reid, M. B. Tedesco, W. E. Gooding, and J. Gerich Glimepiride Improves Both First and Second Phases of Insulin Secretion in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1607 - 1611. [Abstract] [Full Text] [PDF]

				C. A Reasner and B. Goke Overcoming the barriers to effective glycaemic control for type 2 diabetes The British Journal of Diabetes & Vascular Disease, July 1, 2002; 2(4): 290 - 295. [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]